CLINICAL TRIALS PROFILE FOR CHOLYBAR
✉ Email this page to a colleague
All Clinical Trials for CHOLYBAR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05014646 ↗ | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2021-11-15 | This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent. |
| NCT05014646 ↗ | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | Recruiting | City of Hope Medical Center | Phase 2 | 2021-11-15 | This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent. |
| NCT05443425 ↗ | Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies | Not yet recruiting | National Cancer Institute (NCI) | Phase 1 | 2022-12-10 | This phase I trial tests the safety and side effects of leflunomide in combination with steroids in treating patients with acute graft versus host disease who have undergone done stem cell transplant for blood cancers (hematologic malignancies). Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Leflunomide and steroids are immunosuppressive drugs that work in different ways to lower the body's immune response so that the new donor immune cells do not attack the body's normal cells. Giving leflunomide in combination with steroids may help treat acute graft versus host disease in patients after stem cell transplant for hematologic malignancies. |
| NCT05443425 ↗ | Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies | Not yet recruiting | City of Hope Medical Center | Phase 1 | 2022-12-10 | This phase I trial tests the safety and side effects of leflunomide in combination with steroids in treating patients with acute graft versus host disease who have undergone done stem cell transplant for blood cancers (hematologic malignancies). Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Leflunomide and steroids are immunosuppressive drugs that work in different ways to lower the body's immune response so that the new donor immune cells do not attack the body's normal cells. Giving leflunomide in combination with steroids may help treat acute graft versus host disease in patients after stem cell transplant for hematologic malignancies. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CHOLYBAR
Condition Name
Clinical Trial Locations for CHOLYBAR
Trials by Country
Clinical Trial Progress for CHOLYBAR
Clinical Trial Phase
Clinical Trial Sponsors for CHOLYBAR
Sponsor Name
